Gender differences in doxorubicin pharmacology for subjects with chemosensitive cancers of young adulthood.

Zheng LiuJ MartinL OrmeB SeddonJ DesaiW NichollsD ThomsonD PorterG McCowageC UnderhillN CranswickM MichaelM ZacharinA HerschtalJ SivasuthanD M Thomas

Published in: Cancer chemotherapy and pharmacology (2018)

Gender-related differences in doxorubicin pharmacology may account for worse outcomes for male AYAs with chemosensitive cancers compared to females. These findings may reduce the AYA survival gap compared to other age groups.

Keyphrases

drug delivery
cancer therapy
depressive symptoms
mental health
middle aged
adipose tissue
skeletal muscle
young adults
insulin resistance
childhood cancer